Association between genomic metrics and immune infiltration in triple-negative breast cancer

JAMA Oncology

Volumn 3, Issue 12, 2017, Pages E1-E5

  Karn, Thomas ^d   Jiang, Tingting ^a   Hatzis, Christos ^a   Sänger, Nicole ^d   El Balat, Ahmed ^d   Rody, Achim ^b   Holtrich, Uwe ^d   Becker, Sven ^d   Bianchini, Giampaolo ^c   Pusztai, Lajos ^a  

^a YALE CANCER CENTER   (United States)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CORRELATIONAL STUDY; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENOMICS; HUMAN; IMMUNOSURVEILLANCE; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MUTATIONAL LOAD; TRIPLE NEGATIVE BREAST CANCER; TUMOR IMMUNITY; DNA SEQUENCE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PROCEDURES; PROGNOSIS; SEQUENCE ANALYSIS; SURVIVAL ANALYSIS; TUMOR ASSOCIATED LEUKOCYTE;

BIOMARKERS, TUMOR; COHORT STUDIES; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; HUMANS; IMMUNOLOGIC SURVEILLANCE; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; PROGNOSIS; SEQUENCE ANALYSIS, DNA; SEQUENCE ANALYSIS, RNA; SURVIVAL ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85041366005     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.2140     Document Type: Article

References (15)

1. Pusztai L, Karn T, Safonov A, Abu-Khalaf MM, Bianchini G. New strategies in breast cancer: immunotherapy. Clin Cancer Res. 2016;22(9):2105-2110. doi:10.1158/1078-0432.CCR-15-1315
2. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-1570. doi:10.1126/science.1203486
3. Bianchini G, Qi Y, Alvarez RH, et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol. 2010;28(28):4316-4323. doi:10.1200/JCO.2009.27.2419
4. Karn T, Pusztai L, Rody A, Holtrich U, Becker S. The influence of host factors on the prognosis of breast cancer: stroma and immune cell components as cancer biomarkers. Curr Cancer Drug Targets. 2015;15(8):652-664.
5. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1-2):48-61. doi:10.1016/j.cell.2014.12.033
6. Brown SD,Warren RL,Gibb EA, etal. Neo-antigenspredictedbytumorgenome meta-analysiscorrelatewithincreasedpatient survival.GenomeRes.2014;24(5):743-750.doi:10.1101/gr.165985.113
7. Morris LGT, Riaz N, Desrichard A, etal.Pan-cancer analysisofintratumorheterogeneityasaprognostic determinantofsurvival.Oncotarget.2016;7(9):10051-10063.doi:10.18632/oncotarget.7067
8. Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017;355(6322):eaaf8399. doi:10.1126/science.aaf8399
9. Rody A, Karn T, Liedtke C, et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res. 2011;13 (5):R97. doi:10.1186/bcr3035
10. Karn T, Pusztai L, Holtrich U, etal.Homogeneous datasetsoftriplenegativebreastcancersenablethe identificationofnovelprognosticandpredictive signatures.PLoSOne.2011;6(12):e28403.doi:10.1371/journal.pone.0028403
11. Mroz EA, Rocco JW. MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. Oral Oncol. 2013;49(3):211-215. doi:10.1016/j.oraloncology.2012.09.007
12. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333-339. doi:10.1038/nature12634
13. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546-1558. doi:10.1126/science.1235122
14. Safonov A, Jiang T, Bianchini G, et al. Immune gene expression is associated with genomic aberrations in breast cancer [published online April 20, 2017]. Cancer Res. doi:10.1158/0008-5472 .CAN-16-3478
15. Jiang T, Shi W, Wali VB, et al. Predictors of chemosensitivity in triple negative breast cancer: an integrated genomic analysis. PLoS Med. 2016;13 (12):e1002193. doi:10.1371/journal.pmed.1002193